This registry is set up to collect real-world experience in the management of patients with myeloid neoplasms, in particularly in patients with MDS, CMML or AML, treated with hypomethylating agents in Austria and potentially other participating countries. This registry will collect data in a retrospective as well as in a prospective manner at various sites. The aim is to gain valuable insights on both efficacy and toxicity of these drugs in a routine clinical setting in patients with various comorbidities.
Study Type
OBSERVATIONAL
Enrollment
1,500
LKH Feldkirch, Innere Med. II, Interne E
Feldkirch, Austria
LKH Fürstenfeld
Fürstenfeld, Austria
UK Graz: Universitätsklinik für Innere Medizin; Klinische Abteilung für Hämatologie
Graz, Austria
Universitätsklinik für Innere Medizin V
Innsbruck, Austria
Klinikum Klagenfurt: 1. Medizinische Abteilung
Klagenfurt, Austria
UK Krems: Innere Medizin II
Krems, Austria
LKH Hochsteiermark
Leoben, Austria
Ordensklinikum Linz - BHS: Interne I: Medizinische Onkologie und Hämatologie
Linz, Austria
Ordensklinikum Linz - Elisabethinen: Interne I
Linz, Austria
Kepler Universitätsklinikum Linz, Med. Campus III., Univ.-Klinik für Hämatologie und Internistische Onkologie
Linz, Austria
...and 10 more locations
Response evaluation
hematological response, marrow response, cytogenetic response (if data is available), quantification of reduced need for transfusions, median response duration
Time frame: up to 10 years
Overall survival
Time frame: up to 10 years
Documentation of adverse events and toxicities
Time frame: up to 10 years
Number of treatment cycles
Time frame: up to 10 years
Number and reasons of dose reductions
Time frame: up to 10 years
Uni/multivariate analysis of various factors known or thought to influence overall survival in order to establish prognostic markers
Time frame: up to 10 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.